Therapeutic efficacy of novel small molecules like IDH2 inhibitors targeting IDH2, or modulators of the SWI/SNF chromatin complex targeting ARID1B could also be explored in PTCL. This evidence concerns the gene IDH2 and mature T-cell and NK-cell non-Hodgkin lymphoma.